Stablepharma and AFT Pharmaceuticals partner to develop fridge-free anti-infective and oncology injectables

Stablepharma and AFT Pharmaceuticals signed a development and option-to-license agreement to develop fridge-free sterile injectable anti-infective and oncology medicines, in a global market the article values at over USD 6 billion.

Stablepharma has announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines. The initial focus is on anti-infective and oncology treatments in a market the article values at over USD 6 billion. Stablepharma plans to apply its StablevaX™ thermostability technology, previously used for vaccines, to non-vaccine sterile injectables that currently require cold-chain storage. The article mentions AFT is a multinational company listed in Australia and New Zealand and that Stablepharma would be eligible for milestone and royalty payments on commercialisation. Key details: - Agreement type: development and option-to-license between Stablepharma and AFT Pharmaceuticals. - Initial therapeutic targets: anti-infective and oncology sterile injectables. - Market estimate: the article states a total global market valued at over USD 6 billion. - The article states StablevaX™ reformulates products to remain stable at 40°C and above, removing the need for refrigeration. - Commercial terms: Stablepharma may receive milestone and royalty revenue if products are commercialised. - The article states fridge-free products could reduce cold-chain reliance, lower associated CO₂ emissions, and improve access in low-resource settings. Summary: If developed and commercialised, the companies say fridge-free injectables could reduce reliance on cold-chain logistics and broaden access to essential medicines while lowering related CO₂ emissions. Under the agreement, Stablepharma will work on development and AFT holds an option to license; Stablepharma is eligible for future milestone and royalty payments. Timing and regulatory or commercial milestones were not detailed in the article, so next steps and timelines are undetermined at this time.